Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00231907
Status:
COMPLETED
Last Update Posted:
2010-08-27
First Post:
2005-09-30
Brief Title:
A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Influenza Vaccines Mix and Match of Trivalent Inactivated Influenza TIV and Live Attenuated Influenza Vaccine LAIV a Phase I Safety Immunogenicity and Viral Shedding Study
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research is to compare the safety and ability to stimulate antibodies part of the bodies proteins that fight infections of two influenza flu vaccines given to children 12 to 35 months old The two flu vaccines being compared are trivalent inactivated influenza virus vaccine TIV a killed virus vaccine given as a shot licensed for use in children 6 months of age or older and live attenuated influenza vaccine LAIV a live but weakened virus vaccine licensed for children 5 years old and older given as a nose spray The strains of the viruses have been weakened so that they do not cause typical influenza illness but may allow the body to develop protection against the flu LAIV vaccine is not licensed for children less than five years of age therefore its use in this study is investigational Participation is approximately 7 months in duration
Detailed Description:
This multi-site study is a phase I open-label 4-arm trial to evaluate 2 doses of influenza vaccine separated by 30 days The vaccine will either be two doses of a single vaccine or a combination of vaccine products FluMist a cold-adapted live attenuated influenza vaccine LAIV will be administered intranasally via spray applicator Administration of FluMist in children less than 5 years of age is investigational FluZone a trivalent inactivated influenza vaccine TIV licensed for use in children 6 months of age or older will be administered intramuscularly IM to the anterolateral thigh muscle or deltoid muscle Healthy children ages 12 to 35 months old who are representative of the population base of the vaccinating recruitment area will be enrolled in this study at 3 sites The primary study objective is to compare the safety and immunogenicity of two doses of licensed TIV or two doses of licensed LAIV with the safety and immunogenicity of a single dose of LAIV that is boosted with a dose of TIV versus children who receive an initial dose of TIV followed by a booster dose of LAIV among children 12 to 35 months of age The secondary objective is to develop preliminary safety data on these combined vaccine regimes and to evaluate the possibility that a single dose of TIV will either reduce the potential common side effects of LAIV or reduce the viral shedding associated with LAIV in children and to evaluate LAIV as a primary dose vaccine and TIV as a booster vaccine for inducing serum Hemagglutination Inhibition HAI antibodies Vaccinees will be followed post-vaccination for safety reactogenicity and immunogenicity Patterns of viral shedding will be assessed 4 days after vaccination with LAIV A final 6-month post-dose two vaccination contact will be made for serious adverse event data collection Specifically the investigators will assess the ability of LAIV to prime for a secondary immune response when TIV is given as a booster vaccine and the investigators will evaluate TIV as a priming event for LAIV booster vaccine Control groups will include TIVTIV and LAIVLAIV groups The primary outcome measures for the study will be assessment of post-dose 2 hemagglutination inhibition HAI antibodies to each of the 3 strains of influenza contained in the vaccine safety assessment of each of the vaccines in combination vaccine The secondary outcome measures include post-dose 1 HAI antibody titers and viral shedding after intranasal vaccination with live attenuated influenza vaccine An additional secondary outcome will be assessment of secretory Immunoglobulin Ig A in nasal wash samples manifested after 1 or 2 doses of vaccine An additional outcome will be Cell Mediated Immunity after 1 or 2 doses of vaccine Blood will be collected on days 0 30 and 60 for antibody detection Nasal washes will be collected on day 0 30 and 60 for secretory antibody measurements A throat and nose swab sample will be collected on day 3 to 5 post LAIV vaccination to assess viral shedding and as dictated by presence of illness symptoms for viral culturing for two weeks after each dose of either LAIV or TIV vaccine Up to 20 eligible participants will be enrolled in each of the 4 vaccination groups As a four-arm trial with only active vaccine being administered by two different dosing routes there will be no blinding to study assignment Study duration is up to 3 years and individual participant duration is approximately 7 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None